We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $75.65, moving +0.81% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.33%. Elsewhere, the Dow lost 0.4%, while the tech-heavy Nasdaq lost 0.21%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 0.08% over the past month, lagging the Medical sector's gain of 2.35% and the S&P 500's gain of 1.6% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be October 25, 2018. On that day, GILD is projected to report earnings of $1.62 per share, which would represent a year-over-year decline of 28.63%. Meanwhile, our latest consensus estimate is calling for revenue of $5.38 billion, down 17.31% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.58 per share and revenue of $21.55 billion. These totals would mark changes of -25.57% and -17.47%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GILD. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that GILD has a Forward P/E ratio of 11.39 right now. This represents a discount compared to its industry's average Forward P/E of 30.84.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 102, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Gains As Market Dips: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $75.65, moving +0.81% from the previous trading session. This move outpaced the S&P 500's daily loss of 0.33%. Elsewhere, the Dow lost 0.4%, while the tech-heavy Nasdaq lost 0.21%.
Heading into today, shares of the HIV and hepatitis C drugmaker had gained 0.08% over the past month, lagging the Medical sector's gain of 2.35% and the S&P 500's gain of 1.6% in that time.
Investors will be hoping for strength from GILD as it approaches its next earnings release, which is expected to be October 25, 2018. On that day, GILD is projected to report earnings of $1.62 per share, which would represent a year-over-year decline of 28.63%. Meanwhile, our latest consensus estimate is calling for revenue of $5.38 billion, down 17.31% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $6.58 per share and revenue of $21.55 billion. These totals would mark changes of -25.57% and -17.47%, respectively, from last year.
Investors might also notice recent changes to analyst estimates for GILD. Recent revisions tend to reflect the latest near-term business trends. With this in mind, we can consider positive estimate revisions a sign of optimism about the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. Investors can capitalize on this by using the Zacks Rank. This model considers these estimate changes and provides a simple, actionable rating system.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. GILD is holding a Zacks Rank of #3 (Hold) right now.
Valuation is also important, so investors should note that GILD has a Forward P/E ratio of 11.39 right now. This represents a discount compared to its industry's average Forward P/E of 30.84.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 102, putting it in the top 40% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.